154 related articles for article (PubMed ID: 22802313)
1. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs.
Niraula S; Seruga B; Ocana A; Shao T; Goldstein R; Tannock IF; Amir E
J Clin Oncol; 2012 Aug; 30(24):3012-9. PubMed ID: 22802313
[TBL] [Abstract][Full Text] [Related]
2. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.
Niraula S; Amir E; Vera-Badillo F; Seruga B; Ocana A; Tannock IF
J Clin Oncol; 2014 Nov; 32(32):3634-42. PubMed ID: 25267757
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.
Barnes TA; Amir E; Templeton AJ; Gomez-Garcia S; Navarro B; Seruga B; Ocana A
Cancer Treat Rev; 2017 May; 56():1-7. PubMed ID: 28437678
[TBL] [Abstract][Full Text] [Related]
4. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.
Ocana A; Ethier JL; Díez-González L; Corrales-Sánchez V; Srikanthan A; Gascón-Escribano MJ; Templeton AJ; Vera-Badillo F; Seruga B; Niraula S; Pandiella A; Amir E
Oncotarget; 2015 Nov; 6(37):39538-49. PubMed ID: 26446908
[TBL] [Abstract][Full Text] [Related]
5. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade.
Ribnikar D; Goldvaser H; Veitch ZW; Ocana A; Templeton AJ; Šeruga B; Amir E
Sci Rep; 2021 May; 11(1):10843. PubMed ID: 34035370
[TBL] [Abstract][Full Text] [Related]
7. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
8. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
Zhuang SH; Xiu L; Elsayed YA
Cancer J; 2009; 15(5):395-400. PubMed ID: 19826359
[TBL] [Abstract][Full Text] [Related]
9. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two phase 3 studies.
Cantor LB; Liu CC; Batoosingh AL; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1615-20. PubMed ID: 19469697
[TBL] [Abstract][Full Text] [Related]
13. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis.
Ravindran V; Rachapalli S; Choy EH
Rheumatology (Oxford); 2009 Jul; 48(7):807-11. PubMed ID: 19447767
[TBL] [Abstract][Full Text] [Related]
14. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials.
AlHashem HY; Al-Mubarak M; Vera-Badillo FE; Templeton AJ; Ocana A; Seruga B; Amir E
Clin Oncol (R Coll Radiol); 2016 May; 28(5):283-91. PubMed ID: 26542275
[TBL] [Abstract][Full Text] [Related]
15. When are "positive" clinical trials in oncology truly positive?
Ocana A; Tannock IF
J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
[TBL] [Abstract][Full Text] [Related]
16. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations.
Hammad TA; Pinheiro SP; Neyarapally GA
Clin Trials; 2011 Oct; 8(5):559-70. PubMed ID: 21878445
[TBL] [Abstract][Full Text] [Related]
17. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
Wilkerson J; Fojo T
Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis.
Casella G; Ottani F; Pavesi PC; Sangiorgio P; Rubboli A; Galvani M; Fontanelli A; Bracchetti D
Ital Heart J; 2003 Oct; 4(10):677-84. PubMed ID: 14664280
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
